What are the recommendations for initial oral and intravenous antiplatelet therapy in patients with definite or likely NSTE-ACS treated with an initial invasive or ischemia-guided strategy?
Class I 1. Non enteric-coated, chewable aspirin (162 mg to 325 mg) should be given to all patients with NSTE- ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 mg/d to 325 mg/d) should be continued indefinitely (Level of Evidence: A)